A new publication dated August 22, 2026 discusses psychiatric and eye disorders associated with use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs), a drug class that includes dulaglutide. The article, titled "Psychiatric and eye disorders associated with use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs)," appears in Naunyn-Schmiedeberg's Archives of Pharmacology. Dulaglutide is an approved medication within the GLP-1 receptor agonist class covered by this publication. The event record identifies this as a new journal publication rather than a clinical trial result or regulatory action. No specific findings, data points, or conclusions from the publication have been provided beyond its title and journal of record. Readers interested in the full scope of the reported associations should consult the original article directly through the listed source. This brief reports only the existence and bibliographic details of the publication as provided. For general background on dulaglutide, including its approved uses and regulatory status, readers can consult the compound overview.
New Publication Examines Psychiatric, Eye Disorders Linked to GLP-1 RAs Including Dulaglutide
See the full dulaglutide overview
Source: https://pubmed.ncbi.nlm.nih.gov/42629417/